359
Views
8
CrossRef citations to date
0
Altmetric
Review

What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations

&
Pages 245-255 | Published online: 05 May 2021

References

  • PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries. In: Adult Acute Myeloid Leukemia Treatment (PDQ®): Health Professional Version. National Cancer Institute (US); 2002.
  • National Cancer Institute. Acute Myeloid Leukemia - Cancer Stat Facts. SEER; 2013.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Carter JL, Hege K, Yang J, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5.
  • Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87. doi:10.1016/j.blre.2019.04.005
  • Pollyea DA, Bixby D, Perl A, et al. NCCN Guidelines Insights: acute Myeloid Leukemia, Version 2.2021: featured Updates to the NCCN Guidelines. J Nat Comprehen Cancer Network. 2021;19(1):16–27. doi:10.6004/jnccn.2021.0002
  • Halpern AB, Walter RB. Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. Hematology Am Soc Hematol Educ Program. 2020;2020(1):129–134. doi:10.1182/hematology.2020000097
  • Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535–b2535. doi:10.1136/bmj.b2535
  • Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care; 2009.
  • Pandya BJ, Chen -C-C, Medeiros BC, et al. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: a Retrospective Analysis of a Commercial Payer Database. J Manag Care Spec Pharm. 2020;26(7):849–859. doi:10.18553/jmcp.2020.19220
  • Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Curr Med Res Opin. 2017;33(3):519–527. doi:10.1080/03007995.2016.1267615
  • Meyers J, Yu Y, Kaye JA, Davis KL. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11(3):275–286. doi:10.1007/s40258-013-0032-2
  • Reyes C, Engel-Nitz NM, DaCosta Byfield S, et al. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin’s Lymphoma. Oncologist. 2019;24(9):1219–1228. doi:10.1634/theoncologist.2018-0019
  • Marsà A, Ascanio M, Diaz-García J, Darbà J. Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis. J Med Econ. 2020;1–8. doi:10.1080/13696998.2019.1678170
  • Leunis A, Blommestein HM, Huijgens PC, Blijlevens NMA, Jongen-Lavrencic M, Uyl-de Groot CA. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res. 2013;37(3):245–250. doi:10.1016/j.leukres.2012.09.018
  • Hernlund E, Redig J, Rangert Derolf A, et al. Costs per Treatment Phase for AML Patients Receiving High-Dose Chemotherapy in Sweden. Blood. 2019;134(Supplement_1):2154. doi:10.1182/blood-2019-127957
  • Patel SA, Gerber JM, User’s A. Guide to Novel Therapies for Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(5):277–288. doi:10.1016/j.clml.2020.01.011
  • Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9(1):4. doi:10.1186/s40164-020-00161-7
  • Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.6112
  • Kubal TE, Salamanca C, Komrokji RS, et al. Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML. JCO. 2018;36(15_suppl):e19013. doi:10.1200/JCO.2018.36.15_suppl.e19013
  • Mabrey FL, Gardner KM, Shannon Dorcy K, et al. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Adv. 2020;4(4):611. doi:10.1182/bloodadvances.2019000707
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291. doi:10.1182/blood-2017-09-801498
  • Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188(1):129–146. doi:10.1111/bjh.16355
  • Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491–498. doi:10.1182/blood-2013-02-453175
  • Maung KK, Horwitz ME. Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells. Int J Hematol. 2019;110(1):50–58. doi:10.1007/s12185-019-02670-6
  • Cohen S, Roy J, Lachance S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study. Lancet Haematol. 2020;7(2):e134–e145. doi:10.1016/S2352-3026(19)30202-9
  • Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: state of the Art and Future Directions. Front Oncol. 2020;10. doi:10.3389/fonc.2020.00697
  • Kansagra A, Farnia S, Majhail N, Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am Soc Clin Oncol Educ Book. 2020;40:e27–e34. doi:10.1200/EDBK_279151
  • Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. J Natl Cancer Inst. 2019;111(7):719–726. doi:10.1093/jnci/djy193
  • Sikirica S. Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy. ASH; 2020.
  • National Comprehensive Cancer Network, Inc. NCCN® Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia; 2021.
  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971
  • Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389. doi:10.1038/s41375-018-0312-9
  • Stone RM, Mazzola E, Neuberg D, et al. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015;33(11):1252–1257. doi:10.1200/JCO.2014.57.0952
  • Foran JM, Sun Z, Claxton DF, et al. Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. Blood. 2019;134(Supplement_1):115. doi:10.1182/blood-2019-129876
  • Wei AH, Döhner H, Pocock C, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020;383(26):2526–2537. doi:10.1056/NEJMoa2004444